Aptose Biosciences (NASDAQ:APTO) Earns “Buy” Rating from HC Wainwright

Aptose Biosciences (NASDAQ:APTO) (TSE:APS)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $2.00 price target on the biotechnology company’s stock.

Separately, StockNews.com started coverage on Aptose Biosciences in a report on Sunday, February 9th. They set a “hold” rating for the company.

Aptose Biosciences Trading Down 8.8 %

NASDAQ:APTO opened at $0.21 on Wednesday. The stock has a market cap of $12.56 million, a P/E ratio of -0.07 and a beta of 0.88. The stock has a 50 day simple moving average of $0.21 and a 200 day simple moving average of $0.32. Aptose Biosciences has a 1-year low of $0.13 and a 1-year high of $2.08.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp grew its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 75.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 703,384 shares of the biotechnology company’s stock after purchasing an additional 301,634 shares during the period. Sigma Planning Corp owned approximately 1.17% of Aptose Biosciences worth $158,000 as of its most recent SEC filing. 26.62% of the stock is owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.